AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9521635 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavonoids (55 mg daily, predominantly genistein)
Number of subjects: 59
Study 9521635 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 59
Study 8113849 — intervention group
Group type: EXPERIMENTAL
Intervention: FAMe (5‐FU, doxorubicin, and methyl lomustine)
Number of subjects: 252
Study 8113849 — intervention group
Group type: EXPERIMENTAL
Intervention: FAP (5‐FU, doxorubicin, and cisplatin)
Number of subjects: 252
Study 8113849 — intervention group
Group type: EXPERIMENTAL
Intervention: FAMe alternating with TZT (triazinate)
Number of subjects: 252
Study 8113849 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU alone (control)
Number of subjects: 252
Study 2837545 — intervention group
Group type: EXPERIMENTAL
Intervention: Microtraining in six basic communication skills (approximately 25 hours)
Number of subjects: 53
Study 2837545 — intervention group
Group type: EXPERIMENTAL
Intervention: Microtraining in six basic communication skills
Number of subjects: 53
Study 2837545 — intervention group
Group type: COMPARATOR
Intervention: Nonattention control group
Number of subjects: 53
Study 30110103 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic listening
Number of subjects: 50
Study 30110103 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapeutic listening)
Number of subjects: 50
Study 28445783 — intervention group
Group type: EXPERIMENTAL
Intervention: SMA group that combines low‐carbohydrate diet‐focused weight management (WM/SMA) with medication management
Number of subjects: 0
Study 28445783 — intervention group
Group type: COMPARATOR
Intervention: Traditional SMA group focusing on medication management and self‐management counseling
Number of subjects: 0
Study 28445783 — intervention group
Group type: EXPERIMENTAL
Intervention: WM/SMA
Number of subjects: 0
Study 25619124 — intervention group
Group type: EXPERIMENTAL
Intervention: Centchroman 30mg daily for 12 weeks
Number of subjects: 0
Study 25619124 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 10mg daily for 12 weeks
Number of subjects: 0
Study 23933145 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (4 mg) given as nicotine gum
Number of subjects: 12
Study 23933145 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 12
Study 21035560 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 25 μg
Number of subjects: 16
Study 21035560 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 μg
Number of subjects: 16
Study 21035560 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 200 μg
Number of subjects: 16
Study 21035560 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 200 μg
Number of subjects: 16
Study 21035560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 18302293 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic lamivudine treatment
Number of subjects: 0
Study 18302293 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic lamivudine treatment
Number of subjects: 0
Study 17354817 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical analysis of vessel shape using MRA
Number of subjects: 16
Study 12697482 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCBPA) with a mixture of 1% lidocaine and 0.25% bupivacaine, basal infusion of 2 ml/h, bolus dose of 3 ml, lockout time of 45 min.
Number of subjects: 24
Study 12697482 — intervention group
Group type: COMPARATOR
Intervention: Control group without postoperative analgesia.
Number of subjects: 24
Study 10321416 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8 mg once daily for 4 weeks, followed by 16 mg once daily for 4 weeks
Number of subjects: 277
Study 10321416 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8 mg twice daily for 4 weeks
Number of subjects: 277
Study 10321416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 277
Study 10321416 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (once and twice daily)
Number of subjects: 277
Study 10321416 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (once daily)
Number of subjects: 277
Study 8793457 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP (6 cmH2O for ten minutes) in RUAO group
Number of subjects: 37
Study 8793457 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP in asthmatics
Number of subjects: 37
Study 8793457 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP in COPD patients
Number of subjects: 37
Study 8793457 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP in RUAO and asthmatics
Number of subjects: 37
Study 1895355 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadence and power output variations (60, 80, 100 rev min‐1; 100 and 235 W)
Number of subjects: 45
Study 1895355 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadence increase
Number of subjects: 45
Study 1895355 — intervention group
Group type: COMPARATOR
Intervention: Comparison between competitive and recreational cyclists
Number of subjects: 45
Study 7050717 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus chemotherapy with dacarbazine
Number of subjects: 761
Study 7050717 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus immunotherapy with bacille Calmette‐Guérin vaccine
Number of subjects: 761
Study 7050717 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus chemotherapy combined with immunotherapy
Number of subjects: 761
Study 7050717 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 761
Study 30018129 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 0
Study 30018129 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC) chemotherapy
Number of subjects: 0
Study 28193605 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive SBP treatment (goal of <120 mm Hg)
Number of subjects: 107500
Study 26178726 — intervention group
Group type: EXPERIMENTAL
Intervention: C8-dietary oil (13.15 g)
Number of subjects: 12
Study 26178726 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil (19 g)
Number of subjects: 12
Study 26178726 — intervention group
Group type: EXPERIMENTAL
Intervention: Tributyrin (6.53 g)
Number of subjects: 12
Study 26178726 — intervention group
Group type: COMPARATOR
Intervention: Carrots (200 g)
Number of subjects: 12
Study 24152537 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified Airway Risk Index (SARI)
Number of subjects: 70000
Study 24152537 — intervention group
Group type: COMPARATOR
Intervention: Usual non-specific clinical airway assessment
Number of subjects: 70000
Study 21944891 — intervention group
Group type: EXPERIMENTAL
Intervention: 2mg terbutaline nebulised from an Aeroneb Pro (AERO)
Number of subjects: 12
Study 21944891 — intervention group
Group type: COMPARATOR
Intervention: 5mg terbutaline nebulised from a Sidestream (SIDE)
Number of subjects: 12
Study 19138954 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 0
Study 19138954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16307824 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiseptic-impregnated triple-lumen catheter (N=64)
Number of subjects: 133
Study 16307824 — intervention group
Group type: COMPARATOR
Intervention: Standard triple-lumen catheter (N=69)
Number of subjects: 133
Study 14694225 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (dietary advice and increased physical activity)
Number of subjects: 88
Study 14694225 — intervention group
Group type: COMPARATOR
Intervention: Control group (brief leaflet about healthy diet and increased physical activity)
Number of subjects: 88
Study 10875019 — intervention group
Group type: COMPARATOR
Intervention: Image Tracking System (ImagTrac, Olympus, Tokio)
Number of subjects: 0
Study 9175299 — intervention group
Group type: EXPERIMENTAL
Intervention: ARTZ (sodium hyaluronate)
Number of subjects: 90
Study 9175299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 8467341 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilization technique to the involved hip
Number of subjects: 20
Study 8467341 — intervention group
Group type: COMPARATOR
Intervention: Manipulative technique for sacroiliac joint dysfunction
Number of subjects: 20
Study 3007162 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril 5-10-20 mg bid
Number of subjects: 40
Study 3007162 — intervention group
Group type: COMPARATOR
Intervention: propranolol 40-80-120 mg bid
Number of subjects: 40
Study 3007162 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril
Number of subjects: 40
Study 3007162 — intervention group
Group type: COMPARATOR
Intervention: propranolol
Number of subjects: 40
Study 31411273 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital birth satisfaction scale (10 items)
Number of subjects: 16109
Study 31411273 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother's education level
Number of subjects: 16109
Study 31411273 — intervention group
Group type: EXPERIMENTAL
Intervention: Private insurance
Number of subjects: 16109
Study 31411273 — intervention group
Group type: EXPERIMENTAL
Intervention: Having a companion during hospitalization for labor
Number of subjects: 16109
Study 29271813 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized endurance + resistance exercises (ICE)
Number of subjects: 70
Study 29271813 — intervention group
Group type: COMPARATOR
Intervention: Traditional cardiac maintenance program (CMP)
Number of subjects: 70
Study 26690262 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat-sprint training in hypoxia (RSH)
Number of subjects: 10
Study 24646528 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate (antibiotics)
Number of subjects: 159
Study 23462665 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 0
Study 23462665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20669669 — intervention group
Group type: EXPERIMENTAL
Intervention: Liandou Qingmai Recipe (LQR)
Number of subjects: 68
Study 20669669 — intervention group
Group type: COMPARATOR
Intervention: Regular CHD treatment (Control)
Number of subjects: 68
Study 17962631 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS‐FNA
Number of subjects: 40
Study 17962631 — intervention group
Group type: COMPARATOR
Intervention: Surgical staging
Number of subjects: 40
Study 17491169 — intervention group
Group type: EXPERIMENTAL
Intervention: Thematic promotional releases to print and broadcast media
Number of subjects: 2523
Study 17491169 — intervention group
Group type: EXPERIMENTAL
Intervention: Google ads
Number of subjects: 2523
Study 17491169 — intervention group
Group type: EXPERIMENTAL
Intervention: Placement of a link on other websites
Number of subjects: 2523
Study 17491169 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct mailings to ST users
Number of subjects: 2523
Study 17491169 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted mailings to health care and tobacco control professionals
Number of subjects: 2523
Study 17491169 — intervention group
Group type: EXPERIMENTAL
Intervention: Paid advertising
Number of subjects: 2523
Study 12846768 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab
Number of subjects: 38
Study 12846768 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 38
Study 10695392 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose prednisolone (0.5 mg/kg/day)
Number of subjects: 59
Study 10695392 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose prednisolone (1.0 mg/kg/day)
Number of subjects: 59
Study 8997580 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior incision
Number of subjects: 168
Study 8997580 — intervention group
Group type: COMPARATOR
Intervention: Lateral incision
Number of subjects: 168
Study 1596572 — intervention group
Group type: EXPERIMENTAL
Intervention: Trisomy of chromosomes 4 and 10, n = 180
Number of subjects: 1021
Study 1596572 — intervention group
Group type: COMPARATOR
Intervention: Neither or only one of trisomy 4 or 10, n = 73
Number of subjects: 1021
Study 1596572 — intervention group
Group type: EXPERIMENTAL
Intervention: Trisomy of chromosomes 4 and 10, n = 19
Number of subjects: 1021
Study 4028963 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous epinephrine (E) 0.3 mg sub-Q q20min (max 0.9 mg)
Number of subjects: 40
Study 4028963 — intervention group
Group type: COMPARATOR
Intervention: Nebulized metaproterenol (M) 15 mg in 3.0 ml NaCl 0.9% nebulized over 10 minutes
Number of subjects: 40
Study 4028963 — intervention group
Group type: COMPARATOR
Intervention: Nebulized metaproterenol (M)
Number of subjects: 40
Study 4028963 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous epinephrine (E)
Number of subjects: 40
Study 30887687 — intervention group
Group type: EXPERIMENTAL
Intervention: Steamed, dehydrated, and encapsulated placenta (n = 12)
Number of subjects: 27
Study 30887687 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 15)
Number of subjects: 27
Study 30535090 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralose consumption (15% of Acceptable Daily Intake every day for 14 days)
Number of subjects: 66
Study 30535090 — intervention group
Group type: COMPARATOR
Intervention: Control group (same procedures without any intervention)
Number of subjects: 66
Study 27143183 — intervention group
Group type: EXPERIMENTAL
Intervention: LIRA + hUC-MSCs
Number of subjects: 12
Study 27143183 — intervention group
Group type: COMPARATOR
Intervention: LIRA
Number of subjects: 12
Study 24684263 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients (BMI > 95th percentile)
Number of subjects: 48
Study 24684263 — intervention group
Group type: COMPARATOR
Intervention: Normal weight patients (BMI < 85th percentile)
Number of subjects: 48
Study 24684263 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight patients (BMI 85th‐95th percentile)
Number of subjects: 48
Study 20870743 — intervention group
Group type: EXPERIMENTAL
Intervention: Whiteboards in patient rooms on medicine wards
Number of subjects: 0
Study 20870743 — intervention group
Group type: COMPARATOR
Intervention: No whiteboards in surgical wards
Number of subjects: 0
Study 16119515 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg tablets (test formulation)
Number of subjects: 24
Study 16119515 — intervention group
Group type: COMPARATOR
Intervention: Klaricid (reference formulation)
Number of subjects: 24
Study 11864800 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapeutic regimens (specific regimens not detailed)
Number of subjects: 599
Study 9661689 — intervention group
Group type: EXPERIMENTAL
Intervention: IO setting of 35
Number of subjects: 17
Study 9661689 — intervention group
Group type: COMPARATOR
Intervention: IO setting of 15
Number of subjects: 17
Study 8055292 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral electroconvulsive therapy (U‐ECT) with nondominant long-distance parietotemporal electrode placement
Number of subjects: 0
Study 8055292 — intervention group
Group type: COMPARATOR
Intervention: Bilateral bitemporal electroconvulsive therapy (ECT)
Number of subjects: 0
Study 3341801 — intervention group
Group type: EXPERIMENTAL
Intervention: Potent topically administered steroids
Number of subjects: 23
Study 4177135 — intervention group
Group type: EXPERIMENTAL
Intervention: Rh-immune globulin administered at delivery
Number of subjects: 29
Study 11244765 — intervention group
Group type: EXPERIMENTAL
Intervention: roxatidine acetate hydrochloride 150 mg
Number of subjects: 93
Study 31453943 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative neuromuscular training (INT)
Number of subjects: 32
Study 31453943 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 32
Study 30713721 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 422
Study 30713721 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 422
Study 30713721 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg subcutaneously every 2 weeks
Number of subjects: 422
Study 30713721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 422
Study 29980989 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-guided TAP block (TAP-lap)
Number of subjects: 140
Study 29980989 — intervention group
Group type: COMPARATOR
Intervention: Port-site infiltration (PSI)
Number of subjects: 140
Study 26953754 — intervention group
Group type: EXPERIMENTAL
Intervention: Briefed scenarios with a structured 4-minute physician-led briefing
Number of subjects: 38
Study 26953754 — intervention group
Group type: EXPERIMENTAL
Intervention: Briefed scenarios
Number of subjects: 38
Study 26953754 — intervention group
Group type: COMPARATOR
Intervention: Nonbriefed scenarios
Number of subjects: 38
Study 24457144 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa (40μg/kg/hour)
Number of subjects: 64
Study 24457144 — intervention group
Group type: COMPARATOR
Intervention: Control (standard treatment)
Number of subjects: 64
Study 22768630 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritually focused group intervention (11 sessions)
Number of subjects: 43
Study 22768630 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 43
Study 20541828 — intervention group
Group type: EXPERIMENTAL
Intervention: Satavaptan 5mg
Number of subjects: 151
Study 20541828 — intervention group
Group type: EXPERIMENTAL
Intervention: Satavaptan 12.5mg
Number of subjects: 151
Study 20541828 — intervention group
Group type: EXPERIMENTAL
Intervention: Satavaptan 25mg
Number of subjects: 151
Study 20541828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 18022577 — intervention group
Group type: EXPERIMENTAL
Intervention: T cell depletion intervention
Number of subjects: 281
Study 18022577 — intervention group
Group type: COMPARATOR
Intervention: Existing criteria for primary and contributing CODs
Number of subjects: 281
Study 15965356 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (15 mg/d)
Number of subjects: 42
Study 15965356 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate (ISDN) (40 mg/d)
Number of subjects: 42
Study 12468478 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment by appropriately trained nurses
Number of subjects: 1907
Study 12468478 — intervention group
Group type: COMPARATOR
Intervention: Assessment by preregistration house officers
Number of subjects: 1907
Study 9656889 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 20
Study 9656889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7806608 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperactive children
Number of subjects: 0
Study 7806608 — intervention group
Group type: COMPARATOR
Intervention: Matched control children
Number of subjects: 0
Study 2631561 — intervention group
Group type: EXPERIMENTAL
Intervention: Semont's manoeuvre
Number of subjects: 32
Study 2631561 — intervention group
Group type: COMPARATOR
Intervention: Classic habituation exercises
Number of subjects: 32
Study 786429 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine-absorbed Dermatophagoides pteronyssinus vaccine
Number of subjects: 45
Study 786429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 31765228 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week weightbearing protocol
Number of subjects: 70
Study 31765228 — intervention group
Group type: COMPARATOR
Intervention: 12-week weightbearing protocol
Number of subjects: 70
Study 31765228 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined MRI composite score
Number of subjects: 70
Study 31765228 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegner activity score
Number of subjects: 70
Study 31765228 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue structure
Number of subjects: 70
Study 31765228 — intervention group
Group type: EXPERIMENTAL
Intervention: Graft failure on MRI
Number of subjects: 70
Study 31115153 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive OLV
Number of subjects: 67
Study 31115153 — intervention group
Group type: COMPARATOR
Intervention: Conventional OLV
Number of subjects: 67
Study 28732757 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised multimodal exercise training (progressive aerobic, resistance, and balance) for 6 months
Number of subjects: 83
Study 28732757 — intervention group
Group type: COMPARATOR
Intervention: Stretching-and-toning activities (control condition) for 6 months
Number of subjects: 83
Study 26477869 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to a developmental pediatrician
Number of subjects: 1200
Study 26477869 — intervention group
Group type: EXPERIMENTAL
Intervention: General biochemical testing
Number of subjects: 1200
Study 26477869 — intervention group
Group type: EXPERIMENTAL
Intervention: Karyotype genetic testing
Number of subjects: 1200
Study 26477869 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral without testing
Number of subjects: 1200
Study 26477869 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing only
Number of subjects: 1200
Study 26477869 — intervention group
Group type: EXPERIMENTAL
Intervention: Both test and refer
Number of subjects: 1200
Study 23469662 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperineal ultrasonic therapy
Number of subjects: 96
Study 23469662 — intervention group
Group type: COMPARATOR
Intervention: Control group (same machine without ultrasound)
Number of subjects: 96
Study 23469662 — intervention group
Group type: COMPARATOR
Intervention: Comparison between groups A and B after treatment
Number of subjects: 96
Study 21334623 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led clinics
Number of subjects: 180
Study 21334623 — intervention group
Group type: COMPARATOR
Intervention: Physician-led clinics
Number of subjects: 180
Study 18687487 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid access cardiology service (no appointment required)
Number of subjects: 1223
Study 18687487 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure service (part of the rapid access service)
Number of subjects: 1223
Study 16969498 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy plus cystectomy
Number of subjects: 94
Study 16969498 — intervention group
Group type: COMPARATOR
Intervention: Cystectomy alone
Number of subjects: 94
Study 14665549 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 15 micro g kg(‐1) h(‐1) + Propofol 6 mg kg(‐1) h(‐1)
Number of subjects: 27